Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants

Vaccine

Volumn 23, Issue 32, 2005, Pages 4158-4166

  FitzSimons, David ^a   François, Guido ^b   Hall, Andrew ^c   McMahon, Brian ^d   Meheus, André ^b   Zanetti, Alessandro ^e   Duval, Bernard ^f   Jilg, Wolfgang ^g   Böcher, Wulf Otto ^h   Lu, Sheng Nan ⁱ   Akarca, Ulus ^j   Lavanchy, Daniel ^a   Goldstein, Susan ^d   Banatvala, Jangu ^k   Van Damme, Pierre ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e UNIVERSITY OF MILAN   (Italy)

^f INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^g UNIVERSITY OF REGENSBURG   (Germany)

^h JOHANNES GUTENBERG UNIVERSITY   (Germany)

ⁱ CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^j EGE UNIVERSITY   (Turkey)

^k KING'S COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Booster policy; HBV mutants; Hepatitis B; Long term efficacy; Vaccination programmes; Vaccine

Indexed keywords

HEPATITIS B VACCINE;

ARTICLE; GAMBIA; HEALTH CARE POLICY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNIZATION; ITALY; LONG TERM CARE; PRIORITY JOURNAL; SAUDI ARABIA; SINGAPORE; SPAIN; TAIWAN; THAILAND; UNITED STATES; VIRUS MUTANT;

DNA, VIRAL; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; MUTATION; TIME;

EID: 20444483260     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.03.017     Document Type: Article

References (71)

1. A. Hall We have a cancer vaccine - why don't we use it? Trop Med Int Health 3 1998 337 338
2. K.M. Petersen, L.R. Bulkow, B.J. McMahon, C. Zanis, M. Getty, and H. Peters Duration of hepatitis B immunity in a low-risk population receiving hepatitis B vaccinations from birth Pediatr Infect Dis J 23 2004 650 655
3. C.L. Lai, B.C. Wong, E.K. Yeoh, W.L. Lim, W.K. Chang, and H.J. Lin Five-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma-derived vaccine in children: immunogenicity and anamnestic responses Hepatology 18 1993 763 767
4. P.I. Lee, C.Y. Lee, L.M. Huang, and M.H. Chang Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen J Pediatr 126 1995 716 721
5. A. Mele, F. Tancredi, L. Romanò, A. Giuseppone, M. Colucci, and A. Sangiuolo Effectiveness of hepatitis B vaccination in babies born to hepatitis B surface antigen-positive mothers in Italy J Infect Dis 184 2001 905 908
6. R. Trivello, M. Chiaramonte, T. Ngatchu, V. Baldo, S. Majori, and M.E. Moschen Persistence of anti-HBs antibodies in health care personnel vaccinated with plasma-derived hepatitis B vaccine and response to recombinant DNA HB booster vaccine Vaccine 13 1995 139 141
7. H.H. Shih, M.H. Chang, H.Y. Hsu, P.I. Lee, Y.H. Ni, and D.S. Chen Long term immune response of universal hepatitis B vaccination in infancy: a community-based study in Taiwan Pediatr Infect Dis J 18 1999 427 432
8. S.C. Hadler, P.J. Coleman, P. O'Malley, F.N. Judson, and N. Altman Evaluation of long-term protection by hepatitis B vaccine for seven to nine years in homosexual men F.B. Hollinger S.M. Lemon H.S. Margolis Viral hepatitis and liver disease 1991 Williams & Wilkins Baltimore 766 768
9. K. Van Herck, P. Van Damme, S. Thoelen, and A. Meheus Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast-derived hepatitis B vaccine: 8-year results Vaccine 16 1998 1933 1935
10. Y. Poovorawan, A. Theamboonlers, P. Hirsch, T. Vimolket, S. Sinlaparatsamee, and K. Chaiear Persistence of antibodies to the surface antigen of the hepatitis B virus (anti-HBs) in children subjected to the Expanded Programme on Immunization (EPI), including hepatitis-B vaccine, in Thailand Ann Trop Med Parasitol 94 2000 615 621
11. A. Milne, N. Hopkirk, and C.D. Moyes Hepatitis B vaccination in children: persistence of immunity at 9 years J Med Virol 44 1994 113 114
12. R.B. Wainwright, L.R. Bulkow, A.J. Parkinson, C. Zanis, and B.J. McMahon Protection provided by hepatitis B vaccine in a Yupik Eskimo population - results of a 10-year study J Infect Dis 175 1997 674 677
13. P. Coursaget, D. Leboulleux, M. Soumare, P. le Cann, B. Yvonnet, and J.P. Chiron Twelve-year follow-up study of hepatitis B immunization of Senegalese infants J Hepatol 21 1994 250 254
14. G. Da Villa, F. Peluso, L. Picciotto, M. Bencivenga, S. Elia, and M.G. Pelliccia Persistence of anti-HBs in children vaccinated against viral hepatitis B in the first year of life: follow-up at 5 and 10 years Vaccine 14 1996 1503 1505
15. G. Da Villa, M.G. Pelliccia, F. Peluso, E. Ricciardi, and A. Sepe Anti-HBs responses in children vaccinated with different schedules of either plasma-derived or HBV DNA recombinant vaccine Res Virol 148 1997 109 114
16. M. Resti, C. Azzari, F. Mannelli, M.E. Rossi, P. Lionetti, and A. Vierucci Ten-year follow-up study of neonatal hepatitis B immunization: are booster injections indicated? Vaccine 15 1997 1338 1340
17. A. Floreani, V. Baldo, M. Cristofoletti, G. Renzulli, A. Valeri, and C. Zanetti Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers Vaccine 22 2004 607 610
18. A. Berlioz-Arthaud, P. Perolat, and Y. Buisson 10 year assessment of infant hepatitis B vaccination program, in the Loyalty Islands (New Caledonia) Vaccine 1 2003 2737 2742
19. J.S. Wu, L.Y. Hwang, K.J. Goodman, and R.P. Beasley Hepatitis B vaccination in high-risk infants: 10-year follow-up J Infect Dis 179 1999 1319 1325
20. L.M. Huang, B.L. Chiang, C.Y. Lee, P.I. Lee, W.K. Chi, and M.H. Chang Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen Hepatology 29 1999 954 959
21. C.E. Stevens, P.T. Toy, P.E. Taylor, T. Lee, and H.Y. Yip Prospects for control of hepatitis B virus infection: implications of childhood vaccination and long-term protection Pediatrics 90 1992 170 173
22. M.F. Yuen, W.L. Lim, C.C. Cheng, S.K. Lam, and C.L. Lai Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children Hepatology 29 1999 924 927
23. Y.C. Lin, M.H. Chang, Y.H. Ni, H.Y. Hsu, and D.S. Chen Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan J Infect Dis 187 2003 134 138
24. H. Whittle, S. Jaffar, M. Wansbrough, M. Mendy, U. Dumpis, and A. Collinson Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 325 2002 569
25. B.J. McMahon, D. Bruden, K.M. Petersen, L.R. Bulkow, A.J. Parkinson, and O. Nainan Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up Ann Intern Med 142 2005 333 341
26. S.S. Liao, R.C. Li, H. Li, J.Y. Yang, X.J. Zeng, and J. Gong Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children Vaccine 17 1999 2661 2666
27. E.H. Boxall, J. A Sira, N. El-Shuhkri, and D.A. Kelly Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low J Infect Dis 190 2004 1264 1269
28. M.H. Chang, C.J. Chen, M.S. Lai, H.M. Hsu, T.C. Wu, and M.S. Kong For the Taiwan Childhood Hepatoma Study Group. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children N Engl J Med 336 1997 1855 1859
29. K. Huang, and S. Lin Nationwide vaccination: a success story in Taiwan Vaccine 18 Suppl 1 2000 S35 S38
30. A. Safary, and J. Beck Vaccination against hepatitis B: current challenges for Asian countries and future directions J Gastroenterol Hepatol 15 2000 396 401
31. Y.H. Ni, M.H. Chang, L.M. Huang, H.L. Chen, H.Y. Hsu, and T.Y. Chiu Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination Ann Intern Med 135 2001 796 800
32. R. Guan Hepatitis B virus infection in Singapore Gut 38 Suppl 2 1996 S13 S17
33. K.T. Goh Prevention and control of hepatitis B virus infection in Singapore Ann Acad Med Singapore 26 1997 671 681
34. I. Merican, R. Guan, D. Amarapuka, M.J. Alexander, A. Chutaputti, and R.N. Chien Chronic hepatitis B virus infection in Asian countries J Gastroenterol Hepatol 15 2000 1356 1361
35. H.C. Whittle, H. Inskip, A.J. Hall, M. Mendy, R. Downes, and S. Hoare Vaccination against hepatitis B and protection against chronic viral carriage in The Gambia Lancet 337 1991 747 750
36. H.C. Whittle, N. Maine, J. Pilkington, M. Mendy, M. Fortuin, and J. Bunn Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages Lancet 345 1995 1089 1092
37. S. Viviani, A. Jack, A.J. Hall, N. Maine, M. Mendy, and R. Montesano Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age Vaccine 17 1999 2946 2950
38. R. Montesano Hepatitis B immunization and hepatocellular carcinoma: The Gambia Hepatitis Intervention Study J Med Virol 67 2002 444 446
39. J. Chotard, H.M. Inskip, A.J. Hall, F. Loik, M. Mendy, and H. Whittle The Gambia Hepatitis Intervention Study: follow-up of a cohort of children vaccinated against hepatitis B J Infect Dis 166 1992 764 768
40. M. Fortuin, J. Chotard, A.D. Jack, N.P. Maine, M. Mendy, and A.J. Hall Efficacy of hepatitis B vaccine in the Gambian expanded programme on immunisation Lancet 341 1993 1129 1131
41. B.J. McMahon, D. Bruden, K.M. Petersen, L.R. Bulkow, A.J. Parkinson, and M. Khristova Immunogenicity and duration of protection of hepatitis B vaccine: results of a 15-year follow-up Hepatology 32 2000 379A
42. B.J. McMahon, E.R. Rhoades, W.L. Heyward, E. Tower, D. Ritter, and A.P. Lanier A comprehensive programme to reduce the incidence of hepatitis B virus infection and its sequelae in Alaskan Natives Lancet ii 1987 1134 1136
43. R. Harpaz, B.J. McMahon, H.S. Margolis, C.N. Shapiro, D. Havron, and G. Carpenter Elimination of new chronic hepatitis B virus infections: Results of the Alaska immunization program J Infect Dis 181 2000 413 418
44. B. Duval, N. Boulianne, G. De Serres, N. Laflamme, P. De Wals, and R. Masse Comparative immunogenicity under field conditions of two recombinant hepatitis B vaccines in 8-10 year-old children Vaccine 18 2000 1467 1472
45. Y. Poovorawan, A. Theamboonlers, T. Vimolket, S. Sinlaparatsamee, K. Chaiear, and T. Siraprapasiri Impact of hepatitis B immunisation as part of the EPI Vaccine 19 2000 943 949
46. F. Antoñanzas, R. Garuz, J. Rovira, F. Anton, C. Trinxet, and E. Navas Cost-effectiveness analysis of hepatitis B vaccination strategies in Catalonia, Spain Pharmacoeconomics 7 1995 428 443
47. A. Mele, T. Stroffolini, and A.R. Zanetti Hepatitis B in Italy: where we are ten years after the introduction of mass vaccination J Med Virol 67 2002 440 443
48. Viral Hepatitis Prevention Board. Prevention of viral hepatitis in Italy: lessons learnt and the way forward. VHPB meeting report, Catania, Italy, November 7-8, 2002. Viral Hepat 2003;11:2.
49. F.Z. Al-Faleh Hepatitis B infection in Saudi Arabia Ann Saudi Med 8 1988 474 480
50. F.Z. Al-Faleh, E.A. Ayoola, M. Arif, S. Ramia, R. al-Rashed, and M. Al-Jeffry Seroepidemiology of hepatitis B virus infection in Saudi Arabian children: a baseline survey for mass vaccination against hepatitis B J Infect 24 1992 197 206
51. F.Z. Al-Faleh, E.A. Ayoola, M. Al-Jeffri, M. Arif, R.S. Al-Rashed, and S. Ramia Integration of hepatitis B vaccine into the expanded program on immunization: The Saudi Arabian experience Ann Saudi Med 13 1993 231 236
52. F.Z. Al-Faleh, M. Al-Jeffri, S. Ramia, R. Al-Rashed, M. Arif, and M. Rezeig Seroepidemiology of hepatitis B virus infection in Saudi children 8 years after a mass hepatitis B vaccination programme J Infect 38 1999 167 170
53. A.E. Ayoola, M.S. Tobaigy, M.O. Gadour, B.S. Ahmad, M.K. Hamza, and A.M. Ageel The decline of hepatitis B viral infection in South-Western Saudi Arabia. Saudi Med J 24 2003 991 995
54. C. Ferrari, A. Penna, A. Bertoletti, A. Valli, A.D. Antoni, and T. Giuberti Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection J Immunol 145 1990 3442 3449
55. T. Maruyama, A. McLachlan, S. Iino, K. Koike, K. Kurokawa, and D.R. Milich The serology of chronic hepatitis B infection revisited J Clin Invest 91 1993 2586 2595
56. W.O. Böcher, S. Herzog-Hauff, W. Herr, K. Heermann, G. Gerken, and K.H. Meyer zum Büschenfelde Regulation of the neutralizing anti-hepatitis B surface (HBs) antibody response in vitro in HBs vaccine recipients and patients with acute or chronic hepatitis B virus (HBV) infection Clin Exp Immunol 105 1996 52 58
57. W.O. Böcher, S. Herzog-Hauff, J. Schlaak, K.H. Meyer zum Büschenfelde, and H.F. Löhr Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma Hepatology 29 1999 238 244
58. W.O. Böcher, B. Dekel, W. Schwerin, M. Geissler, S. Hoffmann, and A. Rohwer Induction of strong hepatitis B virus (HBV) specific T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera mouse model of chronic HBV infection Eur J Immunol 31 2001 2071 2079
59. W. Jilg, M. Schmidt, and F. Deinhardt Persistence of specific antibodies after hepatitis B vaccination J Hepatol 6 1988 201 207
60. J. Banatvala, P. Van Damme, and S. Oehen Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory Vaccine 19 2000 877 885
61. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000;355:561-5.
62. World Health Organization. Core information for the development of immunization policy. Document WHO/V&B/02.28, 2002. Geneva, WHO, 2002.
63. Centers for Disease Control and Prevention. Hepatitis Surveillance Report No. 59. Atlanta, GA, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2004. http://www.cdc.gov/ncidod/diseases/ hepatitis/resource/PDFs/hep_surveillance_59.pdf [Accessed January 2005].
64. Grosheide P, Van Damme P. Prevention and control of hepatitis B in the community. Communicable Diseases Series, No 1. Antwerpen, Viral Hepatitis Prevention Board, 1996:1-60.
65. G. François, M. Kew, P. Van Damme, M.J. Mphahlele, and A. Meheus Mutant hepatitis B viruses: a matter of academic interest only or a problem with far-reaching implications? Vaccine 19 2001 3799 3815
66. M.P. Cooreman, M.H. van Roosmalen, R. te Morsche, C.M. Sunnen, E.M. de Ven, and J.B. Jansen Characterization of the reactivity pattern of murine monoclonal antibodies against wild-type hepatitis B surface antigen to G145R and other naturally occurring 'a' loop escape mutations Hepatology 30 1999 1287 1292
67. T. Shizuma, K. Hasegawa, K. Ishikawa, T. Naritomi, A. Iizuka, and N. Kanai Molecular analysis of antigenicity and immunogenicity of a vaccine-induced escape mutant of hepatitis B virus J Gastroenterol 38 2003 244 253
68. W.F. Carman, A.R. Zanetti, P. Karayiannis, J. Waters, G. Manzillo, and E. Tanzi Vaccine-induced escape mutant of hepatitis B virus Lancet 336 1990 325 329
69. C.J. Oon, and W.N. Chen Current aspects of hepatitis B surface antigen mutants in Singapore J Viral Hepat 5 Suppl 2 1998 17 23
70. A.J. Zuckerman Effect of hepatitis B virus mutants on efficacy of vaccination Lancet 355 2000 1382 1384
71. World Health Organization. Hepatitis B - HBV mutants. WHO Department of Communicable Disease Surveillance and Response, CSR, 2004. http://www.who.int/ emc-documents/hepatitis/docs/whocdscsrlyo20022/virus/hbv_mutants.html [Accessed January 2005].